Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 3×
“Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide, with an estimated prevalence affecting approximately 25–30% of the global population [1].”
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“Most guidelines recommend a hypocaloric diet with a daily energy deficit of 500–1000 kcal, targeting gradual, sustainable weight loss [22,23].”
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 4×
“The PIVENS trial demonstrated significant improvement in steatohepatitis but not fibrosis among non-diabetic adults with biopsy-proven NASH [38].”
InfluentialThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119 · cited 1×
“This is best captured by the “multiple-hit” theory, which posits that liver steatosis and its progression to steatohepatitis, and fibrosis result from the cumulative, and often simultaneous, impact of several pathogenic factors (Figure 1) [8,9].”
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 5×
“RCTs, including PIVENS, have shown histological improvements in steatosis, lobular inflammation, and hepatocellular ballooning in patients with MASH, especially those with T2DM [13,15,38–40].”
InfluentialEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 1×
“This is best captured by the “multiple-hit” theory, which posits that liver steatosis and its progression to steatohepatitis, and fibrosis result from the cumulative, and often simultaneous, impact of several pathogenic factors (Figure 1) [8,9].”
Assessing mitochondrial dysfunction in cells
Brand, M. D., & Nicholls, D. G. (2011) · Biochemical Journal · doi:10.1042/bj20110162 · Cited by 2,405 · cited 1×
“These effects can contribute to decreased lipid accumulation and improved metabolic homeostasis [127,128].”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“…acid (OCA), the most extensively studied FXR agonist, was evaluated in the FLINT trial (NCT01265498), where non-cirrhotic NASH patients receiving 25 mg daily for 72 weeks experienced notable improvements in liver histology, including reductions in steatosis, inflammation, and fibrosis [65–68].”
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“In the NCT02970942 trial, patients with biopsy-proven NASH and fibrosis stages F1–F3 received daily subcutaneous injections for 72 weeks [74].”
Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005) · JAMA · doi:10.1001/jama.293.1.43 · Cited by 1,726 · cited 1×
“A steady reduction of approximately 0.5 to 1 kg per week is generally recommended, with an initial goal of losing 5–10% of baseline body weight over the course of three to six months [19,20].”
InfluentialLong-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“A steady reduction of approximately 0.5 to 1 kg per week is generally recommended, with an initial goal of losing 5–10% of baseline body weight over the course of three to six months [19,20].”
InfluentialCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · cited 2×
“This weight should ideally be maintained for a similar period before pursuing additional gradual reductions if necessary [13,16].”
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005 · cited 1×
“In contrast, the SYNERGY-NASH trial (NCT04166773) investigated tirzepatide, a dual GLP-1/GIP receptor agonist, in patients with biopsy-confirmed MASH and fibrosis stages F2–F3 [77].”
Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice
Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., Martin, P., Philippe, C., Walker, F., Bado, A., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303816 · Cited by 1,001 · cited 1×
“…and lipotoxicity as the first “hit”, other “hits” include oxidative and endoplasmic reticulum stress, mitochondrial dysfunction, and alterations in the gut–liver axis—particularly dysbiosis and increased intestinal permeability that facilitate translocation of bacterial endotoxins [10,11].”
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“A separate phase 2 study (NCT00501592) in patients with NAFLD and T2DM demonstrated that 25–50 mg of OCA daily for six weeks reduced ALT ( − 9 U/L) and GGT ( − 39 U/L) [69].”
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801 · cited 1×
“Lanifibranor, a pan-PPAR agonist activating α , γ , and δ isoforms, was investigated in two trials (NCT03008070 and NCT03459079) [88–91].”
New Advances in Adaptive Thermogenesis: UCP1 and Beyond
Chouchani, E. T., Kazak, L., & Spiegelman, B. M. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.002 · Cited by 793 · cited 1×
“These effects can contribute to decreased lipid accumulation and improved metabolic homeostasis [127,128].”
Kim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774 · cited 1×
“Activation of this signaling pathway enhances insulin sensitivity, promotes fatty acid oxidation, reduces lipogenesis, and exerts anti-inflammatory effects [117,118].”
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674 · cited 2×
“Among the dietary patterns studied, the Mediterranean diet is the most consistently recommended by international guidelines (EASL-EASD-EASO, ESPEN, and APASL), owing to its high content of monounsaturated and polyunsaturated fats, fiber, antioxidants, and polyphenols [13,22–24].”
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618 · cited 4×
“Despite the proven benefits, maintaining these lifestyle changes can be difficult in real-world settings, particularly among individuals with comorbidities [15].”
InfluentialMolecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610 · cited 1×
“Nevertheless, hepatocyte steatosis remains the central point of the disease, affecting liver function through multiple molecular pathways [3].”
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · cited 1×
“Genetic predispositions like polymorphisms in PNPLA3 or TM6SF2 genes further modulate individual susceptibility and disease course [12,13].”
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570 · cited 1×
“These metabolic alterations lead to hepatocellular lipid accumulation and subsequent lipotoxicity, oxidative stress, mitochondrial dysfunction, and inflammation [5–7].”
Laurin, J., Lindor, K. D., Crippin, J. S., Gossard, A., Gores, G. J., Ludwig, J., Rakela, J., & McGill, D. B. (1996) · Hepatology · doi:10.1002/hep.510230624 · Cited by 566
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550 · cited 1×
“Another FGF21 analog, pegbelfermin (BMS-986036), was investigated in the NCT02413372 phase 2 trial involving patients with a BMI ≥ 25 kg/m 2 [62,63].”
Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
Malhi, H., & Gores, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091980 · Cited by 538 · cited 1×
“These metabolic alterations lead to hepatocellular lipid accumulation and subsequent lipotoxicity, oxidative stress, mitochondrial dysfunction, and inflammation [5–7].”
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · cited 1×
“…of 2.4 mg weekly in patients with compensated cirrhosis, it failed to produce significant improvements in fibrosis or NASH resolution, though beneficial effects on liver fat ( − 38%), liver enzymes, HbA1c ( − 1.4% points), body weight ( − 8.6 kg), and BMI ( − 3.1 units) were still observed [72,73].”
InfluentialA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528 · cited 1×
“In the NCT04771273 trial, survodutide—another dual GLP-1/glucagon receptor agonist—was evaluated in patients with biopsy-proven MASH and fibrosis stages F1– F3 [78].”
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419 · cited 2×
“Inhibition of ACC reduces de novo lipogenesis and may enhance fatty acid oxidation, thereby decreasing hepatic steatosis [49,94].”
Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Königsrainer, A., Maier, K.-P., Bischoff, S. C., & Bergheim, I. (2008) · The Journal of Nutrition · doi:10.1093/jn/138.8.1452 · Cited by 412 · cited 1×
“…and lipotoxicity as the first “hit”, other “hits” include oxidative and endoplasmic reticulum stress, mitochondrial dysfunction, and alterations in the gut–liver axis—particularly dysbiosis and increased intestinal permeability that facilitate translocation of bacterial endotoxins [10,11].”
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398 · cited 1×
“By attenuating this pathway, ASA may help prevent the development of liver fibrosis [131–134].”
AMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383 · cited 1×
“AMP-activated protein kinase (AMPK) serves as a central regulator of cellular energy homeostasis, influencing pathways related to lipid metabolism, glucose uptake, and inflammation [102,103].”
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., et al. (2021) · Hepatology · doi:10.1002/hep.31843 · Cited by 379 · cited 1×
“%) and HbA1c ( − 0.7% points), while increasing HDL cholesterol by +7.6 mg/dL. Saroglitazar, a dual PPAR-α / γ agonist, was studied in the trials NCT03061721 and NCT03863574 [86,87].”
InfluentialHarrison, S. A., Ruane, P. J., Freilich, B. L., Neff, G., Patil, R., Behling, C. A., Hu, C., Fong, E., de Temple, B., Tillman, E. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01425-3 · Cited by 368 · cited 1×
“The NCT03976401 trial assessed efruxifermin, a long-acting FGF21 analog, in patients with a BMI > 25 kg/m 2 and hepatic fat content ≥ 10% [59–61].”
Keam, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02045-0 · Cited by 355 · cited 1×
“…2024 the FDA approved resmetirom, an oral thyroid hormone receptor-β (THR-β ) agonist, in combination with diet and exercise for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stage F2 to F3 fibrosis) [17].”
Mediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353 · cited 1×
“It has demonstrated efficacy in reducing liver fat, improving glycemic control, and lowering cardiovascular risk [25,26].”
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299 · cited 1×
“Separately, the NCT00063232 study evaluated metformin, an indirect AMPK activator, in patients with biopsy-confirmed NASH [55].”
SchÖLmerich, J., Becher, M.-S., Schmidt, K., Schubert, R., Kremer, B., Feldhaus, S., & Gerok, W. (1984) · Hepatology · doi:10.1002/hep.1840040416 · Cited by 294 · cited 1×
“It stabilizes hepatocyte membranes, reduces hepatic transaminase levels in serum, and protects hepatocytes from oxidative stress [43–45].”
Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
Perry, R. J., Zhang, D., Zhang, X.-M., Boyer, J. L., & Shulman, G. I. (2015) · Science · doi:10.1126/science.aaa0672 · Cited by 283 · cited 1×
“Unlike old uncouplers, which pose significant toxicity risks due to uncontrolled mitochondrial disruption, HU6 is designed to achieve a wider therapeutic window of uncoupling that safely enhances mitochondrial energy dissipation [129,130].”
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Viollet, B. (2009) · Frontiers in Bioscience · doi:10.2741/3460 · Cited by 278 · cited 1×
“AMP-activated protein kinase (AMPK) serves as a central regulator of cellular energy homeostasis, influencing pathways related to lipid metabolism, glucose uptake, and inflammation [102,103].”
DGAT1 Is Not Essential for Intestinal Triacylglycerol Absorption or Chylomicron Synthesis
Buhman, K. K., Smith, S. J., Stone, S. J., Repa, J. J., Wong, J. S., Knapp, F. F., Burri, B. J., Hamilton, R. L., Abumrad, N. A., & Farese, R. V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202013200 · Cited by 242 · cited 1×
“In MASLD, excessive activity of these enzymes leads to hepatic steatosis, lipotoxicity, and progression to steatohepatitis and fibrosis [110–112].”
Sex hormones and their receptors regulate liver energy homeostasis
Shen, M., & Shi, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/294278 · Cited by 239
Holmer, M., Lindqvist, C., Petersson, S., Moshtaghi-Svensson, J., Tillander, V., Brismar, T. B., Hagström, H., & Stål, P. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100256 · Cited by 224 · cited 1×
“Intermittent fasting, which focuses on meal timing rather than content, has also shown effects in reducing hepatic steatosis and improving metabolic markers, though comparative data with other diets are limited [30–33].”
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222 · cited 1×
“In the phase 2b ARREST trial (NCT02279524), 247 patients with biopsy-confirmed NASH received 400 mg or 600 mg of aramchol or placebo daily for 52 weeks [56].”
Loomba, R., Mohseni, R., Lucas, K. J., Gutierrez, J. A., Perry, R. G., Trotter, J. F., Rahimi, R. S., Harrison, S. A., Ajmera, V., Wayne, J. D., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.025 · Cited by 220 · cited 1×
“The FASCINATE-1 trial (NCT03938246) evaluated TVB-2640, a first-in-class oral FASN inhibitor, in patients with NAFLD and stage 1–3 fibrosis [57].”
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219 · cited 2×
“Another ACC inhibitor, PF-05221304, was evaluated in several trials (NCT03248882, NCT03776175, and NCT04399538), either as monotherapy or in combination with diacylglycerol acyltrans-ferases 2 (DGAT2) inhibitor PF-06865571 [50–52].”
InfluentialOPTN/SRTR 2022 Annual Data Report: Liver
Kwong, A. J., Kim, W. R., Lake, J. R., Schladt, D. P., Schnellinger, E. M., Gauntt, K., McDermott, M., Weiss, S., Handarova, D. K., Snyder, J. J., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.01.014 · Cited by 217 · cited 1×
“In fact, MASLD is the leading cause of liver transplantation in women and the second leading cause, after alcohol-related liver disease, in men in the United States [14].”
Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis
Kasumov, T., Li, L., Li, M., Gulshan, K., Kirwan, J. P., Liu, X., Previs, S., Willard, B., Smith, J. D., & McCullough, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126910 · Cited by 209
Relationship of sitting time and physical activity with non-alcoholic fatty liver disease
Ryu, S., Chang, Y., Jung, H.-S., Yun, K. E., Kwon, M.-J., Choi, Y., Kim, C.-W., Cho, J., Suh, B.-S., Cho, Y. K., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.07.010 · Cited by 209
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Grander, C., Grabherr, F., & Tilg, H. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad095 · Cited by 199 · cited 3×
“This often leads to delayed diagnosis, by which time the steatosis has been silently progressing for months or years, subtly impairing aspects of metabolic homeostasis such as glycemic control and lipid profiles [4].”
Choi, Y. J., Jeon, S.-M., & Shin, S. (2020) · Nutrients · doi:10.3390/nu12072005 · Cited by 193
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry, R. J., Zhang, D., Guerra, M. T., Brill, A. L., Goedeke, L., Nasiri, A. R., Rabin-Court, A., Wang, Y., Peng, L., Dufour, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2074-6 · Cited by 186 · cited 1×
“It promotes lipolysis, enhances basal energy expenditure, and influences liver lipid metabolism [121–123].”
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175 · cited 1×
“These effects contribute to reduced hepatic steatosis and inflammation and may provide a therapeutic alternative for MASLD patients [119,120].”
Bae, J. C., Suh, S., Park, S. E., Rhee, E. J., Park, C. Y., Oh, K. W., Park, S. W., Kim, S. W., Hur, K. Y., Kim, J. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046819 · Cited by 166 · cited 1×
“Studies have demonstrated that physical activity alone can decrease liver fat by 2% to 50%, depending on intensity and duration [35–37].”
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism
Fisher, F. M., Kim, M., Doridot, L., Cunniff, J. C., Parker, T. S., Levine, D. M., Hellerstein, M. K., Hudgins, L. C., Maratos-Flier, E., & Herman, M. A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.11.008 · Cited by 166 · cited 1×
“Activation of this signaling pathway enhances insulin sensitivity, promotes fatty acid oxidation, reduces lipogenesis, and exerts anti-inflammatory effects [117,118].”
Yoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164 · cited 1×
“By attenuating this pathway, ASA may help prevent the development of liver fibrosis [131–134].”
The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
Xiang, Z., Chen, Y., Ma, H., Ye, Y.-F., Zheng, L., Yang, Y., Li, Y., & Jin, X. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-140 · Cited by 157 · cited 2×
“Some small trials have reported improvements in liver enzymes and steatosis, but histological benefits are uncertain [45–48].”
Trepanowski, J. F., Kroeger, C. M., Barnosky, A., Klempel, M., Bhutani, S., Hoddy, K. K., Rood, J., Ravussin, E., & Varady, K. A. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.018 · Cited by 148
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Siddiqui, M. S., Van Natta, M. L., Connelly, M. A., Vuppalanchi, R., Neuschwander-Tetri, B. A., Tonascia, J., Guy, C., Loomba, R., Dasarathy, S., Wattacheril, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.006 · Cited by 135
Karim, G., Department of Medicine, M. S. I., Bansal, M. B., & Division of Liver Diseases, D. O. M. (2023) · European Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 135 · cited 1×
“THR-β is predominantly expressed in the liver, where its activation promotes fatty acid oxidation and reduces hepatic lipogenesis—key mechanisms relevant to MASLD [141].”
Johari, M. I., Yusoff, K., Haron, J., Nadarajan, C., Ibrahim, K. N., Wong, M. S., Hafidz, M. I. A., Chua, B. E., Hamid, N., Arifin, W. N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47763-8 · Cited by 128
Paik, Y.-H., Kim, J. K., Lee, J. I., Kang, S. H., Kim, D. Y., An, S. H., Lee, S. J., Lee, D. K., Han, K.-H., Chon, C. Y., et al. (2009) · Gut · doi:10.1136/gut.2008.157420 · Cited by 127
EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.018 · Cited by 123 · cited 1×
“EDP-305, a non-bile acid FXR agonist, at a 2.5 mg dose (NCT03421431) led to significant reductions in ALT of up to − 26.1 U/L and liver fat of up to − 6.4% [71].”
InfluentialBarb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Dzen, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.045 · Cited by 116 · cited 1×
“Lanifibranor, a pan-PPAR agonist activating α , γ , and δ isoforms, was investigated in two trials (NCT03008070 and NCT03459079) [88–91].”
Chen, H., Cai, W., Chu, E. S. H., Tang, J., Wong, C.-C., Wong, S. H., Sun, W., Liang, Q., Fang, J., Sun, Z., et al. (2017) · Oncogene · doi:10.1038/onc.2017.73 · Cited by 115
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 114 · cited 2×
“Bile acids are not only essential for lipid digestion but also act as signaling molecules regulating metabolic pathways through receptors like the farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5) [4,104].”
Role of aramchol in steatohepatitis and fibrosis in mice
Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simon, J., Gutiérrez‐de Juan, V., delaCruz‐Villar, L., Azkargorta, M., Lavin, J. L., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1107 · Cited by 113 · cited 1×
“FXR activation in the liver suppresses lipogenic genes via indirect SREBP-1c inhibition and promotes fatty acid oxidation via PPAR α , while in the intestine it regulates fibroblast growth factor 19 (FGF19), a hormone involved in bile acid synthesis feedback [105,106].”
Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0006-5 · Cited by 110
Harrison, S. A., Ruane, P. J., Freilich, B., Neff, G., Patil, R., Behling, C., Hu, C., Shringarpure, R., de Temple, B., Fong, E., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100563 · Cited by 110
Simon, T. G., Wilechansky, R. M., Stoyanova, S., Grossman, A., Dichtel, L. E., Lauer, G. M., Miller, K. K., Hoshida, Y., Corey, K. E., Loomba, R. S., et al. (2024) · JAMA · doi:10.1001/jama.2024.1215 · Cited by 108 · cited 1×
“The phase 2 clinical trial NCT04031729 evaluated the efficacy of low-dose ASA (81 mg daily) over six months in adults with MASLD without cirrhosis [83].”
Branched-Chain Amino Acids and Insulin Resistance, from Protein Supply to Diet-Induced Obesity
Bandt, J. P. D., Coumoul, X., & Barouki, R. (2022) · Nutrients · doi:10.3390/nu15010068 · Cited by 106 · cited 1×
“However, the addition of branched amino acids raises some concerns about the molecular effects of the tested formulations, since both leucine and isoleucine restriction were reported to ameliorate insulin resistance and NAFLD [100,101].”
O’Farrell, M., Duke, G., Crowley, R., Buckley, D., Martins, E. B., Bhattacharya, D., Friedman, S. L., & Kemble, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-19459-z · Cited by 105 · cited 1×
“This reduction in lipotoxic intermediates can alleviate hepatocellular stress, diminish inflammatory responses, and impede the activation of hepatic stellate cells, which are central to fibrogenesis [113,114].”
Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.023 · Cited by 101 · cited 1×
“Vonafexor (NCT03812029), evaluated in the LIVIFY trial, led to reductions in liver fat of up to − 6.3% and reduced ALT by − 16.3 U/L, GGT by − 40.6 U/L, weight by up to − 2.5 kg, and waist circumference by up to − 2.2 cm [70].”
InfluentialSavic, D., Hodson, L., Neubauer, S., & Pavlides, M. (2020) · Nutrients · doi:10.3390/nu12082178 · Cited by 100
Kim, T., Nason, S., Holleman, C., Pepin, M., Wilson, L., Berryhill, T. F., Wende, A. R., Steele, C., Young, M. E., Barnes, S., et al. (2018) · Diabetes · doi:10.2337/db17-1502 · Cited by 97
Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 97 · cited 1×
“Together, these effects reduce glucose and insulin levels, enhance fatty acid β -oxidation, lower insulin resistance, and promote caloric deficit, all relevant to MASLD pathophysiology [24,135,136].”
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96 · cited 1×
“…hepatic steatosis (up to − 21.3%), ALT (up to − 13.6 U/L), AST (up to − 10.2 U/L), GGT (up to − 21.8 U/L), HbA1c (up to − 0.2% points), and HOMA-IR (up to − 0.21 units), highlighting its potential for targeting insulin resistance and hepatic injury in patients with biopsy-proven MASLD [84,85].”
InfluentialAndrogens and Adipose Tissue in Males: A Complex and Reciprocal Interplay
Mammi, C., Calanchini, M., Antelmi, A., Cinti, F., Rosano, G. M. C., Lenzi, A., Caprio, M., & Fabbri, A. (2012) · International Journal of Endocrinology · doi:10.1155/2012/789653 · Cited by 95 · cited 1×
“Testosterone enhances insulin sensitivity by improving insulin signaling pathways and decreasing adipose tissue-derived inflammation [137].”
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction
Gutierrez, J. A., Liu, W., Perez, S., Xing, G., Sonnenberg, G., Kou, K., Blatnik, M., Allen, R., Weng, Y., Vera, N. B., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101196 · Cited by 93 · cited 1×
“In the context of MASLD, excessive dietary fructose intake and elevated hepatic KHK activity have been linked to increased triglyceride synthesis, steatosis, and insulin resistance [124,125].”
Futatsugi, K., Smith, A. C. T., Tu, M., Raymer, B. K., Ahn, K., Coffey, S. B., Dowling, M., Fernando, D. P., Gutierrez, J. A., Huard, K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00944 · Cited by 90 · cited 1×
“Inhibiting KHK may therefore reduce hepatic lipid accumulation and improve metabolic parameters [126].”
Olive oil antioxidants and non-alcoholic fatty liver disease
Abenavoli, L., Milanović, M., Milić, N., Luzza, F., & Giuffrè, A. M. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1634544 · Cited by 89 · cited 1×
“It has demonstrated efficacy in reducing liver fat, improving glycemic control, and lowering cardiovascular risk [25,26].”
Xu, C., Markova, M., Seebeck, N., Loft, A., Hornemann, S., Gantert, T., Kabisch, S., Herz, K., Loske, J., Ost, M., et al. (2020) · Liver International · doi:10.1111/liv.14596 · Cited by 84 · cited 1×
“Other dietary strategies with potential benefits include high-protein diets—especially those emphasizing plant-based proteins—and low-carbohydrate ketogenic diets, which may improve insulin sensitivity and reduce liver fat content [27–29].”
Kazierad, D. J., Chidsey, K., Somayaji, V. R., Bergman, A. J., Birnbaum, M. J., & Calle, R. A. (2021) · Med · doi:10.1016/j.medj.2021.04.007 · Cited by 83 · cited 1×
“The phase 2a trials NCT03969719 and NCT03256526 evaluated PF-06835919, an oral KHK inhibitor, in 164 adults with NAFLD and T2DM [80,81].”
Cooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 83
Sven M., F., Pierre, B., Manal F., A., Quentin M., A., Elisabetta, B., Vlad, R., Philippe, H.-M., Bruno, S., Jean-Louis, J., Pierre, B., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106170 · Cited by 78
Bhattacharya, D., Basta, B., Mato, J. M., Craig, A., Fernández-Ramos, D., Lopitz-Otsoa, F., Tsvirkun, D., Hayardeny, L., Chandar, V., Schwartz, R. E., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100237 · Cited by 75 · cited 1×
“FXR activation in the liver suppresses lipogenic genes via indirect SREBP-1c inhibition and promotes fatty acid oxidation via PPAR α , while in the intestine it regulates fibroblast growth factor 19 (FGF19), a hormone involved in bile acid synthesis feedback [105,106].”
Cusi, K., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou-Bozec, S., Bolze, S., Grouin, J.-M., Jeannin Megnien, S., Dubourg, J., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00300-9 · Cited by 75 · cited 1×
“In the STAMP-NAFLD trial (NCT03763877), the direct AMPK activator PXL770 was evaluated in a randomized, double-blind, placebo-controlled phase 2a study involving 120 patients with hepatic steatosis [54].”
Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01861-9 · Cited by 75 · cited 1×
“The phase 2a clinical trial NCT03205150 investigated licogliflozin, a dual SGLT1/SGLT2 inhibitor [92].”
Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14492 · Cited by 73 · cited 1×
“…acid (OCA), the most extensively studied FXR agonist, was evaluated in the FLINT trial (NCT01265498), where non-cirrhotic NASH patients receiving 25 mg daily for 72 weeks experienced notable improvements in liver histology, including reductions in steatosis, inflammation, and fibrosis [65–68].”
Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men
Sarkar, M., Yates, K., Suzuki, A., Lavine, J., Gill, R., Ziegler, T., Terrault, N., & Dhindsa, S. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.053 · Cited by 71 · cited 1×
“Its anti-inflammatory effects further help suppress hepatic production of pro-inflammatory cytokines and reduce oxidative stress, both of which play a role in the transition from simple steatosis to steatohepatitis and fibrosis [138–140].”
Amin, N. B., Darekar, A., Anstee, Q. M., Wong, V. W., Tacke, F., Vourvahis, M., Lee, D. S., Charlton, M., Alkhouri, N., Nakajima, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-056159 · Cited by 61
Helsley, R. N., Park, S., Vekaria, H. J., Sullivan, P. G., Conroy, L. R., Sun, R. C., Romero, M. D. M., Herrero, L., Bons, J., King, C. D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.010 · Cited by 61 · cited 1×
“In the context of MASLD, excessive dietary fructose intake and elevated hepatic KHK activity have been linked to increased triglyceride synthesis, steatosis, and insulin resistance [124,125].”
Lavallee, C. M., Bruno, A., Ma, C., & Raman, M. (2022) · Nutrients · doi:10.3390/nu14214655 · Cited by 60 · cited 1×
“Intermittent fasting, which focuses on meal timing rather than content, has also shown effects in reducing hepatic steatosis and improving metabolic markers, though comparative data with other diets are limited [30–33].”
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, N., Beyer, C., Shumbayawonda, E., Andersson, A., Yale, K., Rolph, T., Chung, R. T., Vuppalanchi, R., Cusi, K. J., Loomba, R. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.031 · Cited by 60 · cited 1×
“The NCT03976401 trial assessed efruxifermin, a long-acting FGF21 analog, in patients with a BMI > 25 kg/m 2 and hepatic fat content ≥ 10% [59–61].”
Shankar, S. S., Daniels, S. J., Robertson, D., Sarv, J., Sánchez, J., Carter, D., Jermutus, L., Challis, B., & Sanyal, A. J. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.04.017 · Cited by 56 · cited 1×
“The third agent in this class, cotadutide, was assessed in the NCT04019561 trial involving patients with NAFLD or NASH and fibrosis stages F1–F3 [79].”
SGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48 · cited 1×
“Together, these effects reduce glucose and insulin levels, enhance fatty acid β -oxidation, lower insulin resistance, and promote caloric deficit, all relevant to MASLD pathophysiology [24,135,136].”
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48 · cited 1×
“These effects contribute to reduced hepatic steatosis and inflammation and may provide a therapeutic alternative for MASLD patients [119,120].”
Matsukawa, T., Yagi, T., Uchida, T., Sakai, M., Mitsushima, M., Naganuma, T., Yano, H., Inaba, Y., Inoue, H., Yanagida, K., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.161282 · Cited by 48 · cited 1×
“This reduction in lipotoxic intermediates can alleviate hepatocellular stress, diminish inflammatory responses, and impede the activation of hepatic stellate cells, which are central to fibrogenesis [113,114].”
Noureddin, M., Khan, S. M., Portell, F. R., Jorkasky, D. K., Dennis, J., Khan, O., Johansson, L., Johansson, E., & Sanyal, A. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00198-x · Cited by 46 · cited 2×
“The phase 2a clinical trial NCT04874233 evaluated HU6, an oral prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP), in individuals with NAFLD [82].”
Shen, W., Middleton, M. S., Cunha, G. M., Delgado, T. I., Wolfson, T. J., Gamst, A. C., Fowler, K. J., Alazraki, A. L., Trout, A. T., Ohliger, M. A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.027 · Cited by 45
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44 · cited 1×
“In NCT04216589, conducted in patients with NAFLD and HIV, semaglutide led to reductions in steatosis ( − 4.2%), HbA1c, weight ( − 7.8 kg), BMI ( − 2.8 units), and waist circumference ( − 6.7 cm) [75].”
InfluentialGlucagon-induced extracellular cAMP regulates hepatic lipid metabolism
Lv, S., Qiu, X., Li, J., Liang, J., Li, W., Zhang, C., Zhang, Z., & Luan, B. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0649 · Cited by 42 · cited 1×
“It promotes lipolysis, enhances basal energy expenditure, and influences liver lipid metabolism [121–123].”
Siddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A., & Sanyal, A. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.018 · Cited by 42 · cited 1×
“%) and HbA1c ( − 0.7% points), while increasing HDL cholesterol by +7.6 mg/dL. Saroglitazar, a dual PPAR-α / γ agonist, was studied in the trials NCT03061721 and NCT03863574 [86,87].”
InfluentialSaxena, A. R., Lyle, S., Khavandi, K., Qiu, R., Whitlock, M., Esler, W. P., & Kim, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14946 · Cited by 41 · cited 1×
“The phase 2a trials NCT03969719 and NCT03256526 evaluated PF-06835919, an oral KHK inhibitor, in 164 adults with NAFLD and T2DM [80,81].”
Fernández‐Ramos, D., Lopitz‐Otsoa, F., delaCruz‐Villar, L., Bilbao, J., Pagano, M., Mosca, L., Bizkarguenaga, M., Serrano‐Maciá, M., Azkargorta, M., Iruarrizaga‐Lejarreta, M., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5101 · Cited by 39 · cited 1×
“Although ileal bile acid transporter (IBAT) inhibition may reduce intestinal FXR signaling, increased hepatic bile acid production could enhance hepatic FXR activity, supporting improved lipid and glucose metabolism [107].”
Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
Machado, M. V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s304357 · Cited by 39 · cited 1×
“Regular exercise has been shown to improve insulin sensitivity, reduce hepatic fat accumulation, and lower markers of inflammation and oxidative stress—key drivers in MASLD progression [34].”
Rajewski, P., Cieściński, J., Rajewski, P., Suwała, S., Rajewska, A., & Potasz, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010217 · Cited by 39 · cited 1×
“The effect of dietary interventions and lifestyle changes in MASLD has been profoundly reviewed recently [21].”
Chee, N., Sinnanaidu, R. P., & Chan, W. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16723 · Cited by 36 · cited 1×
“Despite moderate improvements in transaminases and histology, concerns remain about long-term safety, including a possible increased risk of prostate cancer in older men and hemorrhagic stroke [41,42].”
Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort
Byambasukh, O., Zelle, D. M., & Corpeleijn, E. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000168 · Cited by 35 · cited 1×
“Studies have demonstrated that physical activity alone can decrease liver fat by 2% to 50%, depending on intensity and duration [35–37].”
Zalewska, A., Szarmach, I. J., Żendzian‐Piotrowska, M., & Maciejczyk, M. (2020) · Nutrients · doi:10.3390/nu12020458 · Cited by 32 · cited 1×
“N-acetylcysteine replenishes intracellular glutathione stores, reducing oxidative stress—a key driver of hepatocellular injury in MASLD [95,96].”
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Harrison, S. A., Alkhouri, N., Ortiz‐Lasanta, G., Rudraraju, M., Tai, D., Wack, K., Shah, A., Besuyen, R., Steineger, H. H., Fraser, D. A., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.032 · Cited by 30 · cited 1×
“The ICONA trial (NCT04052516) evaluated icosabutate, an oral free fatty acid receptor 1 and 4 (FFAR1/FFAR4) agonist, in patients with biopsy-confirmed MASH and fibrosis stages F1–F3 [58].”
Targeting acetyl-CoA carboxylases for the treatment of MASLD
Mateo-Marín, M. A., & Alves‐Bezerra, M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100676 · Cited by 28 · cited 1×
“Inhibition of ACC reduces de novo lipogenesis and may enhance fatty acid oxidation, thereby decreasing hepatic steatosis [49,94].”
Zhang, G. Y., & Brandman, D. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.6431 · Cited by 27 · cited 5×
“To assist in the non-invasive evaluation of liver fibrosis and guide treatment strategies, clinical scoring systems like FIB-4, along with transient elastography, have been developed to facilitate risk stratification (Figure 2) [2].”
InfluentialHarrison, S. A., Baum, S. J., Gunn, N., Younes, Z. H., Kohli, A., Patil, R., Koziel, M. J., Chera, H., Zhao, J., & Chakravarthy, M. V. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001375 · Cited by 26 · cited 1×
“These concepts were tested in the phase 2 clinical trial NCT04073368, which evaluated the safety and efficacy of two investigational amino acid-based formulations—AXA1125 and AXA1957—in patients with NASH [53].”
Vitamin E for people with non-alcoholic fatty liver disease
Wen, H.-Z., Deng, H., Yang, L., Li, L., Lin, J., Zheng, P., Bjelaković, M., & Ji, G. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015033.pub2 · Cited by 26
Luo, Y., Decato, B. E., Charles, E. D., Shevell, D. E., McNaney, C. A., Shipkova, P. A., Apfel, A., Tirucherai, G., & Sanyal, A. J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100392 · Cited by 25 · cited 1×
“Another FGF21 analog, pegbelfermin (BMS-986036), was investigated in the NCT02413372 phase 2 trial involving patients with a BMI ≥ 25 kg/m 2 [62,63].”
Szukiewicz, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062501 · Cited by 25 · cited 1×
“In the context of MASLD, FFAR4 activation may reduce hepatic inflammation and fibrosis by attenuating inflammatory responses and improving insulin sensitivity [115,116].”
Meyers, C. D., Serrano‐Wu, M. H., Amer, A., Chen, J., Rocheford, E. C., Commerford, R., Hubbard, B. K., Brousseau, M., Li, L., Meihui, P., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.093 · Cited by 24 · cited 1×
“In MASLD, excessive activity of these enzymes leads to hepatic steatosis, lipotoxicity, and progression to steatohepatitis and fibrosis [110–112].”
Anti-Atherosclerotic Potential of Free Fatty Acid Receptor 4 (FFAR4)
Kiepura, A., Stachyra, K., & Olszanecki, R. (2021) · Biomedicines · doi:10.3390/biomedicines9050467 · Cited by 23 · cited 1×
“In the context of MASLD, FFAR4 activation may reduce hepatic inflammation and fibrosis by attenuating inflammatory responses and improving insulin sensitivity [115,116].”
Ketogenic, hypocaloric diet improves nonalcoholic steatohepatitis
Belopolsky, Y., Khan, M. Q., Sonnenberg, A., Davidson, D., & Fimmel, C. J. (2020) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2020-0005 · Cited by 22 · cited 1×
“Other dietary strategies with potential benefits include high-protein diets—especially those emphasizing plant-based proteins—and low-carbohydrate ketogenic diets, which may improve insulin sensitivity and reduce liver fat content [27–29].”
LPCN 1144 Resolves NAFLD in Hypogonadal Males
Albhaisi, S. A. M., Kim, K., Baker, J., Chidambaram, N., Patel, M. V., Charlton, M., & Sanyal, A. J. (2020) · Hepatology Communications · doi:10.1002/hep4.1571 · Cited by 22 · cited 1×
“The phase 2 LiFT trial (NCT04134091) evaluated LPCN 1144, an oral prodrug of testosterone, in men with biopsy-confirmed NASH and fibrosis stages F1–F3 [93].”
Zhang, W., Tang, Y., Huang, J., Ren, H., Yang, Y., Qin-bing, Y., & Hu, H. (2019) · Research Square · doi:10.21203/rs.2.15906/v1 · Cited by 22
Efficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis
Liu, A., Cai, Y., Yuan, Y., Liu, M., Zhang, Z., Xu, Y., & Jiao, P. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02238-w · Cited by 22 · cited 1×
“Carnitine, on the other hand, is essential for mitochondrial fatty acid transport and β -oxidation, may enhance lipid metabolism, and mitigates hepatic steatosis [97–99].”
Alemany, M. (2012) · HORMONES · doi:10.14310/horm.2002.1356 · Cited by 21 · cited 1×
“Its anti-inflammatory effects further help suppress hepatic production of pro-inflammatory cytokines and reduce oxidative stress, both of which play a role in the transition from simple steatosis to steatohepatitis and fibrosis [138–140].”
Armstrong, M. J., Okanoue, T., Palle, M. S., Sejling, A., Tawfik, M., & Roden, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16065 · Cited by 21 · cited 1×
“…of 2.4 mg weekly in patients with compensated cirrhosis, it failed to produce significant improvements in fibrosis or NASH resolution, though beneficial effects on liver fat ( − 38%), liver enzymes, HbA1c ( − 1.4% points), body weight ( − 8.6 kg), and BMI ( − 3.1 units) were still observed [72,73].”
InfluentialSivakumar, P., Saul, M. E., Robinson, D., King, L. E., & Amin, N. B. (2024) · Scientific Reports · doi:10.1038/s41598-024-67843-8 · Cited by 18
Raji, A., Gantz, I., Crutchlow, M. F., Flynn, H., Xu, L., Rodgers, A. J., Krishnan, R., Rizk, M. L., Hu, S., Kaufman, K. D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70038 · Cited by 17 · cited 1×
“In contrast, NCT04583423 evaluated MK-3655, a humanized monoclonal antibody that activates FGFR1c/ β -Klotho signaling by binding KLB [64].”
Yin, H., Yuan, F., Jiao, F., Niu, Y., Jiang, X., Deng, J., Guo, Y., Chen, S., Zhai, Q., Hu, C., et al. (2021) · Diabetes · doi:10.2337/db21-0336 · Cited by 16 · cited 1×
“However, the addition of branched amino acids raises some concerns about the molecular effects of the tested formulations, since both leucine and isoleucine restriction were reported to ameliorate insulin resistance and NAFLD [100,101].”
Monternier, P., Singh, J., Parasar, P., Theurey, P., DeWitt, S. H., Jacques, V., Klett, E. L., Kaur, N., Nagaraja, T. N., Moller, D. E., et al. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12510 · Cited by 16 · cited 1×
“…hepatic steatosis (up to − 21.3%), ALT (up to − 13.6 U/L), AST (up to − 10.2 U/L), GGT (up to − 21.8 U/L), HbA1c (up to − 0.2% points), and HOMA-IR (up to − 0.21 units), highlighting its potential for targeting insulin resistance and hepatic injury in patients with biopsy-proven MASLD [84,85].”
InfluentialApproach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Zalewska, A., Zięba, S., Kostecka-Sochoń, P., Kossakowska, A., Żendzian‐Piotrowska, M., Matczuk, J., & Maciejczyk, M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8831855 · Cited by 15 · cited 1×
“N-acetylcysteine replenishes intracellular glutathione stores, reducing oxidative stress—a key driver of hepatocellular injury in MASLD [95,96].”
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15 · cited 1×
“Additionally, elevated bile acid levels in the colon stimulate TGR5 receptors on enteroendocrine L-cells, leading to increased secretion of glucagon-like peptide-1 (GLP-1), which may provide additional effects in treatments targeting bile acid metabolism in MASLD [108].”
Zhang, W., Tang, Y., Huang, J., et al. (2020) · PubMed · doi:10.6133/apjcn.202012_29(4).0004 · Cited by 15
Bruls, Y. M. H., den Kamp, Y. J. M. O., Veeraiah, P., Perez, R. Z., Phielix, E., Havekes, B., Schaart, G., Moonen‐Kornips, E., Berendsen, B. R. B., Virmani, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16298 · Cited by 10 · cited 1×
“Carnitine, on the other hand, is essential for mitochondrial fatty acid transport and β -oxidation, may enhance lipid metabolism, and mitigates hepatic steatosis [97–99].”
Aseem, S. O., Wang, J., Kalaiger, M. F., Way, G. W., Zhao, D., Tai, Y., Gurley, E. C., Zeng, J., Wang, X., Cowart, L. A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000748 · Cited by 8
Vlasova, K. Y., Ostroverkhov, P. V., Vedenyapina, D., Iakimova, T. M., Trusova, A., Lomakina, G. Y., Vodopyanov, S., Grin, M. A., Klyachko, N. L., Chekhonin, V. P., et al. (2022) · Nanomaterials · doi:10.3390/nano12132162 · Cited by 5 · cited 1×
“Unlike old uncouplers, which pose significant toxicity risks due to uncontrolled mitochondrial disruption, HU6 is designed to achieve a wider therapeutic window of uncoupling that safely enhances mitochondrial energy dissipation [129,130].”
Szukiewicz, D. (2025) · Preprints.org · doi:10.20944/preprints202502.1303.v1 · Cited by 4
Aseem, S. O., Way, G. W., Wang, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.621880 · Cited by 1 · cited 1×
“Therapeutic strategies targeting bile acid metabolism, such as stearoyl-CoA desat-urase 1 (SCD1) inhibition by aramchol and IBAT inhibition by elobixibat, aim to restore metabolic balance and mitigate liver damage in MASLD [109].”
Cited by
Wang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 46
“21 The diagnostic workflow of MASLD integrates multiple approaches: 22,23 (1) Liver biopsyremains the gold standard for evaluating steatosis grade (SAF score), lobular inflammation, and fibrosis stage (NASH CRN scoring); (2) Non-invasive scores, particularly the FIB-4 index (incorporating age, ALT,…”
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 40
“1,72 While promising, these agents are primarily preventive rather than curative in HCC, and their protective effects must be confirmed in large MASLD-focused trials.”
Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review)
Ma, Q., Liu, K., Chang, C., Wang, L., Shen, Z.-Y., Li, J., Adu, M., Lin, Q., Huang, H., Wu, X., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5668 · Cited by 23
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 20
Ma, J., Xie, N., Wang, Z., Liang, X., Han, Y., Zhao, Q., Wang, M., Lu, H., Kou, W., Alazawi, W., et al. (2026) · Advanced Science · doi:10.1002/advs.202519109 · Cited by 14
Metadata
- Authors
- Drygalski, K.
- Affiliations
- Gdańsk Medical University (PL)
- Corresponding author
- Drygalski, Krzysztof
- ORCID
- Drygalski, Krzysztof
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-07-07
- Volume
- 26
- Issue
- 13
- Pages
- 6518
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12249978
- OpenAlex
- W4412088572
- Cited by
- 39
- References
- 141
- Citations by year
- 2026: 34 · 2025: 5
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- non-alcoholic fatty liver disease, pharmacotherapy, GLP-1 receptor agonists, PPAR agonists, FXR agonists, acetyl-CoA carboxylase inhibitors, hepatic steatosis, drug development, obesity, type 2 diabetes, metabolic syndrome
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


